We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




POC Tests Evaluated for Filarial Antigenemia

By LabMedica International staff writers
Posted on 28 Sep 2017
Print article
Image: The Alere Filariasis Test Strip (FTS) (Left panel, strong positive) and The BinaxNOW Filariasis Immunochromatographic card (Right pane, weak positivel) are in vitro immunodiagnostic tests used to detect Wuchereria bancrofti antigen in whole blood, serum, or plasma (Photo courtesy of Dr. Peter U Fischer).
Image: The Alere Filariasis Test Strip (FTS) (Left panel, strong positive) and The BinaxNOW Filariasis Immunochromatographic card (Right pane, weak positivel) are in vitro immunodiagnostic tests used to detect Wuchereria bancrofti antigen in whole blood, serum, or plasma (Photo courtesy of Dr. Peter U Fischer).
Lymphatic filariasis (LF) is a major neglected tropical disease (NTD) that has been targeted for elimination by 2020. The Global Programme to Eliminate Lymphatic Filariasis (GPELF, launched in 2000) uses repeated rounds of mass drug administration (MDA) with antifilarial drugs to interrupt transmission of the parasite.

Antigen testing is more sensitive for filarial infection than tests that detect microfilariae (Mf) in night blood. Point-of-care (POC) antigen tests can be performed with finger prick blood collected during the day or night, and they provide a visual result in 10 minutes. The performance of two POCs has been compared.

An international team of scientists working with those at Washington University School of Medicine (Saint Louis, MO, USA) compared the tests prior to MDA in two study sites (Congo and Côte d'Ivoire) and in three sites that had received MDA (Democratic Republic of Congo and two sites in Liberia). Data were analyzed with regard to positivity, agreement and heterogeneity. Models evaluated potential effects of age, gender, and blood microfilaria (Mf) counts in individuals and effects of endemicity and history of MDA at the village level.

The two POCs tested were the BinaxNOW Filariasis Immunochromatographic card test (ICT), and the more recently introduced Alere Filariasis Test Strip (FTS) both from Alere. All individuals with positive ICT and/or FTS tests were asked to provide a second blood sample between 10:00 PM and 1:00 AM for assessment of Wuchereria bancrofti Mf. In West Africa, fingerprick blood was collected in capillary tubes with EDTA anticoagulant, and this blood was used to prepare Mf smears.

The team analyzed the test results from a total of 3,682 individuals. FTS test scores in persons with positive test results were often higher than ICT scores (46.3% in pre-MDA sites and 35.2% in post-MDA sites). Only 14 subjects (0.4%) were ICT-positive and FTS-negative. Eleven of these cases were from Côte d'Ivoire (pre-MDA), and four of the 12 individuals with this profile who provided night blood were microfilaremic. Antigenemia rates were 8% and 22% higher by FTS than by ICT in pre-MDA and in post-MDA sites, respectively. FTS/ICT ratios were higher in areas with low infection rates.

The authors concluded that their study provided extensive new information on the performance of the FTS compared to ICT in Africa and it has confirmed the increased sensitivity of FTS reported in prior studies. Variability in FTS/ICT was related in part to endemicity level, history of MDA, and perhaps to the medications used for MDA. These results suggest that FTS should be superior to ICT for mapping, for transmission assessment surveys, and for post-MDA surveillance. The study was published on September 11, 2017, in the journal Public Library of Science Neglected Tropical Diseases.

Related Links:
Washington University School of Medicine

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Hemoglobin/Haptoglobin Assay
IDK Hemoglobin/Haptoglobin Complex ELISA
New
Alpha-Fetoprotein Reagent
AFP Reagent Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.